Skip to main content
Erschienen in: Current Urology Reports 5/2010

01.09.2010

Urodynamics in the Evaluation of Overactive Bladder

verfasst von: Eric S. Rovner, Colin M. Goudelocke

Erschienen in: Current Urology Reports | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Overactive bladder (OAB) is a clinical syndrome characterized by urinary urgency, frequency, and nocturia with or without accompanying urinary incontinence. Thus, using this operational definition based on symptoms at presentation, urodynamic testing is not required for an initial diagnosis of OAB. An increasing body of evidence suggests that, although there is a relationship between the urodynamic finding of detrusor overactivity and OAB, these are quite separate findings, and successful response to nonsurgical and surgical interventions for OAB does not depend on finding detrusor overactivity on urodynamic testing. The role of urodynamics in the setting of OAB is not well defined at present, but there are several clinical scenarios where such testing may be useful. However, at this time, the evidence to support their routine use in patients with OAB is limited.
Literatur
1.
Zurück zum Zitat Abrams P, Cardozo L, Fall M, et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002, 187:116–126.CrossRefPubMed Abrams P, Cardozo L, Fall M, et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002, 187:116–126.CrossRefPubMed
2.
Zurück zum Zitat Abrams P: Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003, 62(5 Suppl 2):28–37.CrossRefPubMed Abrams P: Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003, 62(5 Suppl 2):28–37.CrossRefPubMed
3.
Zurück zum Zitat •• Nitti VW, Rovner ES, Bavendam T: Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int 2010, 105:1268–1275. In this report from a randomized placebo-controlled trial of fesoterodine, response of overactive bladder symptoms to antimuscarinic treatment was not dependent on finding of detrusor overactivity on pretreatment urodynamics. CrossRefPubMed •• Nitti VW, Rovner ES, Bavendam T: Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int 2010, 105:1268–1275. In this report from a randomized placebo-controlled trial of fesoterodine, response of overactive bladder symptoms to antimuscarinic treatment was not dependent on finding of detrusor overactivity on pretreatment urodynamics. CrossRefPubMed
4.
Zurück zum Zitat •• Malone-Lee JG, Al-Buheissi S: Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 2009, 103:931–937. In this trial of tolterodine-ER, patients were stratified into groups of patients with and without pretreatment detrusor overactivity. Presence of detrusor overactivity could not be used to predict response to treatment or placebo, suggesting that urodynamic assessment of detrusor overactivity may not be required before treatment of overactive bladder with antimuscarinic therapy. CrossRefPubMed •• Malone-Lee JG, Al-Buheissi S: Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 2009, 103:931–937. In this trial of tolterodine-ER, patients were stratified into groups of patients with and without pretreatment detrusor overactivity. Presence of detrusor overactivity could not be used to predict response to treatment or placebo, suggesting that urodynamic assessment of detrusor overactivity may not be required before treatment of overactive bladder with antimuscarinic therapy. CrossRefPubMed
5.
Zurück zum Zitat Eric R: Urodynamic results and clinical outcomes with intravesical botulinum toxin a (onabotuliumtoxina) in a randomized, placebo-controlled, dose-finding study in idiopathic overactive bladder. J Urol 2010, 183(4 Suppl):e591–e592. Eric R: Urodynamic results and clinical outcomes with intravesical botulinum toxin a (onabotuliumtoxina) in a randomized, placebo-controlled, dose-finding study in idiopathic overactive bladder. J Urol 2010, 183(4 Suppl):e591–e592.
6.
Zurück zum Zitat • South MM, Romero AA, Jamison MG, et al.: Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation. Int Urogynecol J Pelvic Floor Dysfunct 2007, 18:1395–1398. This retrospective review found that patients characterized as responders to test neurostimulation for overactive bladder were not more likely to have detrusor overactivity on pretreatment urodynamics than those who failed to respond to a test stimulation, suggesting that detrusor overactivity is not a requirement for test neurostimulation. CrossRefPubMed • South MM, Romero AA, Jamison MG, et al.: Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation. Int Urogynecol J Pelvic Floor Dysfunct 2007, 18:1395–1398. This retrospective review found that patients characterized as responders to test neurostimulation for overactive bladder were not more likely to have detrusor overactivity on pretreatment urodynamics than those who failed to respond to a test stimulation, suggesting that detrusor overactivity is not a requirement for test neurostimulation. CrossRefPubMed
7.
Zurück zum Zitat Digesu GA, Khullar V, Cardozo L, Salvatore S: Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003, 22:105–108. (Published erratum appears in Neurourol Urodyn 2003, 22:356.)CrossRefPubMed Digesu GA, Khullar V, Cardozo L, Salvatore S: Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003, 22:105–108. (Published erratum appears in Neurourol Urodyn 2003, 22:356.)CrossRefPubMed
8.
Zurück zum Zitat Hashim H, Abrams P: Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006, 175:191–194.CrossRefPubMed Hashim H, Abrams P: Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006, 175:191–194.CrossRefPubMed
9.
Zurück zum Zitat Lowenstein L, Pham T, Abbasy S, et al.: Observations relating to urinary sensation during detrusor overactivity. Neurourol Urodyn 2009, 28:497–500.CrossRefPubMed Lowenstein L, Pham T, Abbasy S, et al.: Observations relating to urinary sensation during detrusor overactivity. Neurourol Urodyn 2009, 28:497–500.CrossRefPubMed
10.
Zurück zum Zitat Renganathan A, Cartwright R, Cardozo L, et al.: Quality control in urodynamics: Analysis of an international multi-center study. Neurourol Urodyn 2009, 28:380–384.CrossRefPubMed Renganathan A, Cartwright R, Cardozo L, et al.: Quality control in urodynamics: Analysis of an international multi-center study. Neurourol Urodyn 2009, 28:380–384.CrossRefPubMed
11.
Zurück zum Zitat Heslington K, Hilton P: Ambulatory monitoring and conventional cystometry in asymptomatic female volunteers. Br J Obstet Gynaecol 1996, 103:434–441.PubMed Heslington K, Hilton P: Ambulatory monitoring and conventional cystometry in asymptomatic female volunteers. Br J Obstet Gynaecol 1996, 103:434–441.PubMed
12.
Zurück zum Zitat Lee SR, Kim HJ, Kim A, Kim JH: Overactive bladder is not only overactive but also hypersensitive. Urology 2010, 75:1053–1059.CrossRefPubMed Lee SR, Kim HJ, Kim A, Kim JH: Overactive bladder is not only overactive but also hypersensitive. Urology 2010, 75:1053–1059.CrossRefPubMed
13.
Zurück zum Zitat Ho CH, Tai HC, Yu HJ: Urodynamic findings in female diabetic patients with and without overactive bladder symptoms. Neurourol Urodyn 2010, 29:424–427.PubMed Ho CH, Tai HC, Yu HJ: Urodynamic findings in female diabetic patients with and without overactive bladder symptoms. Neurourol Urodyn 2010, 29:424–427.PubMed
14.
Zurück zum Zitat Guralnick ML, Grimsby G, Liss M, et al.: Objective differences between overactive bladder patients with and without urodynamically proven detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 2010, 21:325–329.CrossRefPubMed Guralnick ML, Grimsby G, Liss M, et al.: Objective differences between overactive bladder patients with and without urodynamically proven detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 2010, 21:325–329.CrossRefPubMed
15.
16.
Zurück zum Zitat Maake C, Landman M, Wang X, et al.: Expression of smoothelin in the normal and the overactive human bladder. J Urol 2006, 175:1152–1157.CrossRefPubMed Maake C, Landman M, Wang X, et al.: Expression of smoothelin in the normal and the overactive human bladder. J Urol 2006, 175:1152–1157.CrossRefPubMed
17.
Zurück zum Zitat Rapp DE, Lyon MB, Bales GT, Cook SP: A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinary dysfunction. Eur Urol 2005, 48:303–308.CrossRefPubMed Rapp DE, Lyon MB, Bales GT, Cook SP: A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinary dysfunction. Eur Urol 2005, 48:303–308.CrossRefPubMed
18.
Zurück zum Zitat Ford AP, Gever JR, Nunn PA, et al.: Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol 2006, 147(Suppl 2):S132–S143.CrossRefPubMed Ford AP, Gever JR, Nunn PA, et al.: Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol 2006, 147(Suppl 2):S132–S143.CrossRefPubMed
19.
Zurück zum Zitat De Laet K, De Wachter S, Wyndaele JJ: Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 2006, 25:156–161.CrossRefPubMed De Laet K, De Wachter S, Wyndaele JJ: Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 2006, 25:156–161.CrossRefPubMed
20.
Zurück zum Zitat Iijima K, De Wachter S, Wyndaele JJ: Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 2007, 52:842–847.CrossRefPubMed Iijima K, De Wachter S, Wyndaele JJ: Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 2007, 52:842–847.CrossRefPubMed
21.
Zurück zum Zitat Boy S, Schurch B, Mehnert U, et al.: The effects of tolterodine on bladder-filling sensations and perception thresholds to intravesical electrical stimulation: method and initial results. BJU Int 2007, 100:574–578.CrossRefPubMed Boy S, Schurch B, Mehnert U, et al.: The effects of tolterodine on bladder-filling sensations and perception thresholds to intravesical electrical stimulation: method and initial results. BJU Int 2007, 100:574–578.CrossRefPubMed
22.
Zurück zum Zitat Finney SM, Andersson KE, Gillespie JI, Stewart LH: Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 2006, 98:503–507.CrossRefPubMed Finney SM, Andersson KE, Gillespie JI, Stewart LH: Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 2006, 98:503–507.CrossRefPubMed
23.
Zurück zum Zitat Panayi DC, Tekkis P, Fernando R, Khullar V: Is the beneficial effect of antimuscarinics related to motor or sensory changes in the bladder? Int Urogynecol J Pelvic Floor Dysfunct 2010, 21:841–845.CrossRefPubMed Panayi DC, Tekkis P, Fernando R, Khullar V: Is the beneficial effect of antimuscarinics related to motor or sensory changes in the bladder? Int Urogynecol J Pelvic Floor Dysfunct 2010, 21:841–845.CrossRefPubMed
24.
Zurück zum Zitat Juszczak K, Ziomber A, Wyczolkowski M, Thor PJ: Urodynamic effects of the bladder C-fiber afferent activity modulation in chronic model of overactive bladder in rats. J Physiol Pharmacol 2009, 60:85–91.PubMed Juszczak K, Ziomber A, Wyczolkowski M, Thor PJ: Urodynamic effects of the bladder C-fiber afferent activity modulation in chronic model of overactive bladder in rats. J Physiol Pharmacol 2009, 60:85–91.PubMed
25.
Zurück zum Zitat Goldman HB, Vasavada SP: Female urology: a practical clinical guide. Totowa, NJ: Humana Press; 2007. Goldman HB, Vasavada SP: Female urology: a practical clinical guide. Totowa, NJ: Humana Press; 2007.
26.
Zurück zum Zitat Sahai A, Khan MS, Le Gall N, et al.: Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology 2008, 71:455–459.CrossRefPubMed Sahai A, Khan MS, Le Gall N, et al.: Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology 2008, 71:455–459.CrossRefPubMed
27.
Zurück zum Zitat Cohen BL, Barboglio P, Rodriguez D, Gousse AE: Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009, 28:205–208.CrossRefPubMed Cohen BL, Barboglio P, Rodriguez D, Gousse AE: Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009, 28:205–208.CrossRefPubMed
28.
Zurück zum Zitat • Groenendijk PM, Lycklama a Nyeholt AA, Heesakkers JP, et al.: Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int 2008, 101:325–329. This study of patients with neurostimulator placement for overactive bladder found that even those patients with pretreatment detrusor overactivity on urodynamics who had resolution of their detrusor overactivity 6 months later while the stimulator was on had no difference in rates of improvement in symptoms over those patients who had no resolution of detrusor overactivity. CrossRefPubMed • Groenendijk PM, Lycklama a Nyeholt AA, Heesakkers JP, et al.: Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int 2008, 101:325–329. This study of patients with neurostimulator placement for overactive bladder found that even those patients with pretreatment detrusor overactivity on urodynamics who had resolution of their detrusor overactivity 6 months later while the stimulator was on had no difference in rates of improvement in symptoms over those patients who had no resolution of detrusor overactivity. CrossRefPubMed
Metadaten
Titel
Urodynamics in the Evaluation of Overactive Bladder
verfasst von
Eric S. Rovner
Colin M. Goudelocke
Publikationsdatum
01.09.2010
Verlag
Current Science Inc.
Erschienen in
Current Urology Reports / Ausgabe 5/2010
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-010-0130-8

Weitere Artikel der Ausgabe 5/2010

Current Urology Reports 5/2010 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.